Bruker Corporation has announced the acquisition of biocrates life sciences ag, a leader in mass spectrometry-based quantitative metabolomics, located in Innsbruck, Austria. This acquisition is part of Bruker's strategy to expand its multiomics solutions by integrating biocrates' expertise in metabolite and lipid analysis kits, assays, software, and services. The move aims to enhance Bruker's capabilities in MS-based metabolomics and supports its growth plans in metabolomics and lipidomics. Financial details of the transaction were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.